Evidence map›Paper›PMID 38515845›Full record

ArticleFrontiers in pharmacology2024

Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes.

Yongru Chen, Jingxian Chen, Shuo Zhang, Dan Zhu, Feiying Deng, Rui Zuo, Yufei Hu, Yue Zhao, Yale Duan, Benwei Lin and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

Yongru Chen *The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Jingxian Chen *School of Public Health, Shantou University, Shantou, China.
Shuo ZhangThe First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Dan ZhuDepartment of Endocrine and Metabolic Diseases, Longhu People's Hospital, Shantou, China.
Feiying DengThe First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Rui ZuoSchool of Public Health, Shantou University, Shantou, China.
Yufei HuSchool of Public Health, Shantou University, Shantou, China.
Yue ZhaoSchool of Medicine, Tulane University, New Orleans, LA, United States.
Yale DuanDepartment of Medical Affairs, Hanson (Shanghai) Health Technology Co, Ltd, Shanghai, China.
Benwei LinSchool of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, United Kingdom.
Fengwu ChenThe First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Yun LiangShantou University Medical College, Shantou, China.
Jiaxiong ZhengSchool of Public Health, Shantou University, Shantou, China.
Barkat Ali KhanDrug Delivery and Cosmetic Lab (DDCL), Gomal Center of Pharmaceutical Sciences, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan.
Kaijian HouSchool of Public Health, Shantou University, Shantou, China.
Shantou University · CNFirst Affiliated Hospital of Shantou University Medical College · CNGomal University · PKShanghai Medical Information Center · CNTulane University · USUniversity of Bristol · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

continuous glucose monitoringglucagon-like peptide-1 receptor agonistsoral antidiabetic drugstime in rangetype 2 diabetes

Identifiers

PMID38515845
PMCPMC10955089
OpenAlexW4392558155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.